Indium-111-octreotide, a somatostatin analog is the first commercially available receptor-based agent. It shares the binding site of naturally occurring somatostatin and is suitable for imaging somatostatin receptor-bearing tumors. An 111In-octreotide scan performed on a 6-wk old girl showed increased uptake in a subcutaneous cavernous hemangioma, which should be added to the list of lesions that can be visualized on an octreotide scan.